NCT03920566View on ClinicalTrials.gov

The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs

UnknownOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Drug Interaction
Interventions
OTHER

Anti-Xa level

Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment

Sponsors

Collaborators (1)

Pharmacy Research UK
All Listed Sponsors
collaborator

Pharmacy Research UK

UNKNOWN

collaborator

University of Brighton

OTHER

lead

Royal Marsden NHS Foundation Trust

OTHER